TTR and aceruloplasminemia: Tafamidis partially decreased the frequency of TFNEs and contrast enhancement in two patients with the TTR Y69H variant of hereditary ATTR amyloidosis; however, cerebellar ataxia and cognitive impairment gradually progressed.